Publications by authors named "Samantha Steiger"
Isavuconazonium sulfate (ISA) is a triazole antifungal approved for the treatment of invasive aspergillosis and mucormycosis in adults. This single-center, retrospective review of pediatric oncology and stem cell transplant patients receiving ISA for prophylaxis (n=20) or treatment (n=6) of invasive fungal disease (IFD) aims to characterize real-world clinical efficacy and toxicity of ISA in patients <18 years of age. Of 20 patients receiving ISA for prophylaxis, three patients had presumed breakthrough IFD (1 proven, 2 probable/possible).
View Article and Find Full Text PDFArticle Synopsis
- - AZD7442 is a combination therapy of two monoclonal antibodies designed to prevent COVID-19 in high-risk patients, particularly those with hematologic cancers who may not respond well to vaccines.
- - A study involving 892 high-risk patients at Memorial Sloan Kettering Cancer Center found that 10.9% experienced breakthrough infections, but most were treated outpatient and had low hospitalization rates.
- - Patients receiving updated dosing regimens of AZD7442 had a lower likelihood of breakthrough infections, but no clear predictors for infection risk were identified, suggesting the treatment's effectiveness regardless of individual risk factors.
Article Synopsis
- - Sotrovimab is a monoclonal antibody aimed at preventing severe COVID-19 cases in high-risk patients, including those with hematologic cancers, although limited research has been done on its effect in this specific group.
- - In a study of 156 cancer patients treated with sotrovimab, 11% were hospitalized due to COVID-19, with significant factors for hospitalization being anti-CD20 therapy and having relapse or refractory disease.
- - The findings suggest that while sotrovimab can reduce COVID-19 severity, patients on anti-CD20 therapy face higher risks, indicating a need to investigate combination treatments to improve outcomes.
Objective: To characterize bacterial infections and antibiotic utilization in hospitalized cancer patients with coronavirus disease 2019 (COVID-19).
Design: Retrospective cohort study.
Setting: Tertiary cancer center in New York City.
Background: Historically, there is perceived pressure to achieve therapeutic levels of tacrolimus quickly after heart transplant (HT). We evaluated the association between time within therapeutic tacrolimus range and time to therapeutic trough and rejection in the 30 days following HT.
Methods: This is a single-center retrospective cohort study of consecutive adult HT patients receiving immunosuppression.
Candida spp. are the fourth leading cause of nosocomial blood stream infections in North America. Candida glabrata is the second most frequently isolated species, and rapid development of antifungal resistance has made treatment a challenge.
View Article and Find Full Text PDFClinical and economic implications of urinary tract infections.
Expert Rev Pharmacoecon Outcomes Res
August 2017
Urinary tract infections represent one of the most frequent reasons for hospitalization. As a result of their prevalence from community-based origins as well as those which develop in hospital setting, this constellation of infections represents a tremendous burden to the global healthcare system. Areas covered: Over the last several decades the management of these infections has become more complicated due to the underlying comorbid conditions of the patients as well as escalating antimicrobial resistance to many of the most frequently used oral and parenteral agents.
View Article and Find Full Text PDF